Treatment Of Pulmonary Heart Disease Research Articles

Exosomes derived from induced cardiopulmonary progenitor cells alleviate acute lung injury in mice.

Cardiopulmonary progenitor cells (CPPs) constitute a minor subpopulation of cells that are commonly associated with heart and lung morphogenesis during embryonic development but completely subside after birth. This fact offers the possibility for the treatment of pulmonary heart disease (PHD), in which the lung and heart are both damaged. A reliable source of CPPs is urgently needed. In this study, we reprogrammed human cardiac fibroblasts (HCFs) into CPP-like cells (or induced CPPs, iCPPs) and evaluated the therapeutic potential of iCPP-derived exosomes for acute lung injury (ALI). iCPPs were created in passage 3 primary HCFs by overexpressing GLI1, WNT2, ISL1 and TBX5 (GWIT). Exosomes were isolated from the culture medium of passage 6-8 GWIT-iCPPs. A mouse ALI model was established by intratracheal instillation of LPS. Four hours after LPS instillation, ALI mice were treated with GWIT-iCPP-derived exosomes (5 × 109, 5 × 1010 particles/mL) via intratracheal instillation. We showed that GWIT-iCPPs could differentiate into cell lineages, such as cardiomyocyte-like cells, endothelial cells, smooth muscle cells and alveolar epithelial cells, in vitro. Transcription analysis revealed that GWIT-iCPPs have potential for heart and lung development. Intratracheal instillation of iCPP-derived exosomes dose-dependently alleviated LPS-induced ALI in mice by attenuating lung inflammation, promoting endothelial function and restoring capillary endothelial cells and the epithelial cells barrier. This study provides a potential new method for the prevention and treatment of cardiopulmonary injury, especially lung injury, and provides a new cell model for drug screening.

Brief Discussion on Observation on the Clinical Effect of Qiliqiangxin Capsule in the Treatment of Pulmonary Heart Disease and Heart Failure

Brief Discussion on Observation on the Clinical Effect of Qiliqiangxin Capsule in the Treatment of Pulmonary Heart Disease and Heart Failure

Clinical Value of Low Molecular Weight Heparin in Treatment of Pulmonary Heart Disease Complicated With Respiratory Failure

It is aimed to investigate the clinical value of low-molecular-weight heparin in treatment of pulmonary heart disease complicated with respiratory failure. Between January 2018 and April 2019, we included 120 pulmonary heart disease patients complicated with respiratory failure in this study and divided them into two groups using the double-blind, random method, i.e. the control group and the observation group, with 60 patients in each group. After admission, patients in two groups undertook the regular treatment, while those in the observation group additionally took low molecular weight heparin at 5000 U via subcutaneous injection, twice per d. Before and after treatment, arterial blood-gas indicators [partial pressure of carbon dioxide, partial pressure of oxygen and pH value] and the indicators of hemorheology (high blood viscosity, hematocrit and fibrinogen) and clinical efficacy were evaluated for patients in two groups. Prior to the treatment, comparison of the levels of partial pressure of carbon dioxide, partial pressure of oxygen, pH value, high blood viscosity, hematocrit and fibrinogen between two groups showed no significant differences, while after treatment, significant improvement was demonstrated in these indicators in the observation group as compared to those in the control group (p 0.05). In the observation group, patients had an effectiveness rate of 88.33 % (53/60), significantly higher than 63.33 % (38/60) in the control group (p 0.05), while patients in the observation group had shorter hospitalization time [(14.7±0.4) d] than that [(16.9±0.3) d] in the control group (p<0.05). For pulmonary heart disease patients complicated with respiratory failure, medication of low-molecular-weight heparin gained promising efficacy, with significant improvement in the blood performance, ventilation, and heart and lung functions of patients, thereby increasing the survival rate and shortening the hospitalization time of patients. Thus, it is worthy of being promoted in clinical practice.

Isosorbide mononitrate injection in the treatment of pulmonary heart disease

Objective To explore the efficacy and safety of isosorbide mononitrate injection in the treatment of pulmonary heart disease.Methods 138 patients with pulmonary heart disease were randomly divided into two groups,69 for each group.The patients in the control group received conventional treatments including anti-infection,improvement in heart function,diuresis,relief of dyspnea,and oxygen inhalation; while the patients in the study group received isosorbide mononitrate injection in addition to conventional therapies.The clinical efficacy and cardiac function were observed in both groups before and after treatment.Results The study group was markedly superior to the control group in the improvement of symptoms,hemorheology,and TCD indexes.The total effectiveness rate was 89.86％ in the study group and 75.36％ in the control group; the efficacy differed significantly between the two groups (P＜0.05).Conclusions The study group has a quicker onset,stronger action,and better efficacy and is more reliable and safer than the control group. Key words: Isosorbide mononitrate; Pulmonary heart disease; Efficacy

A Rational Approach to the Diagnosis and Treatment of Pulmonary Heart Disease

CONCLUSION It should be realised that the diagnosis of cor pulmonale on physical examination can be made only in advanced cases. Its presence should be suspected in any patient with chronic respiratory disease. Further investigations should be undertaken if clinical evidence is not yet at hand. Prevention and prompt treatment of acute respiratory infection is the main aim in the management of patients with cor pulmonale. Should cardiac failure be present, administration of antibiotics is an essential part of treatment. Oxygen therapy must be carried out with due regard to the possibility of carbon dioxide narcosis supervening. Our thanks are due to the General Superintendent of our teaching hospital for permission to use records and to the physicians who allowed us to quote their cases.